Skip to content

Search

Australian parents oblivious to true danger of the flu

New research investigating the devastating impact of the 2017 flu season by PAEDS-FluCAN, a national collaboration observing influenza in children, confirmed it was time to take action after thousands of children were hospitalised with the virus last year.

New national guideline set to tackle skin infections

When health organisations in the north-west of WA requested urgent action to address the region’s high rate of skin infections, Dr Asha Bowen answered the call.

Babies at risk due to delayed vaccinations

As many as a quarter of Australian babies aren’t getting vaccinated on time, leaving them at risk of developing life-threatening illnesses such as whooping cough when they are most vulnerable.

Early ear infections linked to higher risk of future problems: study

Researchers have found kids who experience repeat ear infections in infancy have a much higher risk of ongoing problems with ear infections in later childhood

New ear health study music to the ears of Aboriginal children

Wait times for Aboriginal children suffering ear infections could be reduced to less than four weeks thanks to a new The Kids Research Institute Australia research project

$3.4mill to improve treatment management of cystic fibrosis

The Kids researchers have been awarded over $3.4 million for a new trial to pioneer improved ways for managing cystic fibrosis (‘CF’).

Skin infections send eight out of every 100 Aboriginal babies to hospital

In a WA first, researchers from The Kids Research Institute Australia have shown that Aboriginal babies are 22.5 times more likely to be treated for skin infections than non-Aboriginal babies.

New meningococcal strains bring increased risk in WA

A new study has confirmed the changing pattern of meningococcal disease in Western Australia.

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Clinical outcomes and severity of laboratory-confirmed RSV compared with influenza, parainfluenza and human metapneumovirus in Australian children attending secondary care

Acute lower respiratory infections (ALRIs) are a major contributor to the global infectious disease burden and a common cause of hospitalisation for children under 2 years. We compared clinical severity in children hospitalised with respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV) and influenza virus (IFV).